Dr. Randall K. Wolf, MD, FACS, FACC is the CEO of WOLF™ CARDIO LLC, and the inventor of the WOLF™ CardioClip multifunction device. He is a cardiovascular surgeon and a pioneer in the minimally invasive surgical treatment of atrial fibrillation (AFib). He has performed close to 3,000 Wolf Procedures since the first one in 2003 and has demonstrated the procedure to over 800 heart surgeons worldwide. Dr. Wolf has been an invited professor delivering hundreds of lectures at hospitals, academic meetings, and seminars in the United States and abroad.
He is currently a member of the DeBakey Heart and Vascular Center at the Houston Methodist Hospital in the Texas Medical Center. He serves as the arrhythmia specialist of the group.
Mr. Stuart Breslin is the founder and President of Conversions Consulting LLC; a company focused on impactful medical device development. Over the last 10 years, Mr. Breslin has helped both small and large Pharma identify and develop novel technologies for the administration of their medicines.
Prior to consulting, Mr. Breslin worked for Eli Lilly and Company. Over a 34-year career, he had a variety of roles in Parenteral Products, Planning, Dry Products, Final Purification and finally 16 years in medical device development.
Under his guidance, Lilly's medical device group improved hoe people administered their medication with the development of a number of innovative technologies including HumaPen® Luxura™, HumaPen® Memoir™, Humalog® KwikPen™, HumaPen® Savvio™, and the autoinjectors for Trulicity®, Taltz®, Emgality®, Zepbound® and Monjaro®.
Gary Solomon is a patent attorney who helps large companies develop strategic global patent portfolios, and whose business experience is sought by startups and midsize clients to integrate a comprehensive IP strategy into business execution for maximum growth and exit sale value.
A partner with Foley & Lardner LLP, Gary is a member of the firm’s Electronics Practice who focuses on patent preparation, prosecution, and the monetization and protection of these intellectual property assets.
Gary has years of experience developing large and strategic patent portfolios for his clients, as well as conducting IP due diligence; drafting legal opinions relating to utility and design patents, including patentability, non-infringement, freedom-to-operate, invalidity and design-around opinions; and participating in a number of IP transactions, including acquisition, funding, and company sales.
Jim Collins is a Biopharmaceutical and medical device executive who focused on creation of innovative delivery devices that help people take their medicine as conveniently as possible.
He built two of the best delivery device development teams in the BioPharmaceutical industry at Eli Lilly and Sanofi. Using human centered design principles, he partnered with world class design, development, and manufacturing companies to ideate, develop, and launch multiple market leading delivery device technologies.
Key accomplishments include the creation at Lilly of market leading insulin KwikPen Platform, the Trulicity pen Platform, the Talz pen Platform, the Savvio Pen, the Forteo Pen, and many others. At Sanofi, multiple devices were developed for Toujeo, Soliqua, Praluent, Kevzara, and Dupixent including the development and launch of a number of first to market delivery systems including the first 2mL PFS safety system with BD, and the first to market 2mL autoinjector in partnership with SHL.
Joe Fahed, M.D., F.A.C.C., F.H.R.S. graduated with high honors from the Saint Joseph University Medical School in Beirut, Lebanon. He completed his Internal Medicine residency at the University of Massachusetts Medical School where he was awarded Intern of the Year and served as Chief Medical Resident. He went on to complete a fellowship in Cardiovascular Diseases at the University of Massachusetts before moving to Philadelphia, where he finished a two-year fellowship in Advanced Clinical Cardiac Electrophysiology at the prestigious Hospital of University of Pennsylvania.
He specializes in the diagnosis and management of complex cardiac arrhythmias. He is trained in ablation of both atrial and ventricular arrhythmias, as well as epicardial ablation. He also implants and manages cardiac devices (pacemakers, defibrillators, and cardiac resynchronization therapy [CRT]).
Efrain A. Miranda, Ph.D. is the CEO of Clinical Anatomy Associates, Inc. A former professor of Anatomy and Neuroanatomy at the University of Chile Medical College, he also serves as an Adjunct Associate Professor of Anatomy at the Cell Biology, Anatomy and Neuroanatomy Department of the University of Cincinnati College of Medicine. Dr. Miranda is an active member of the American Association of Clinical Anatomists (AACA) and the Human Anatomy and Physiology Association. He served as a Presidential Appointee to the Clinical Anatomical Terminology Committee of the AACA.
Dr. Miranda has a diverse clinical and business background. He has held several positions in the medical devices industry including Marketing Director and member of the Management Board of Johnson & Johnson Chile.
Tapan Rami, M.D., F.A.C.C., F.H.R.S. graduated Summa Cum Laude from the University of California, Riverside in Biomedical Sciences. He earned his MD from the University of California, Los Angeles, where he was elected into membership of Alpha Omega Alpha medical honor society.
He went on to complete his residency and fellowships in Internal Medicine and Cardiovascular Diseases at the Baylor College of Medicine in Houston. He completed further training in a Cardiac Electrophysiology fellowship at the University of Pennsylvania Medical Center in Philadelphia.
He has numerous research publications and presentations.
When catheter ablation was in its infancy, radiofrequency current was introduced to replace the riskier, high-energy shocks associated with direct current. However, progress was slow due to small lesions created by standard catheters.
Enter Warren Jackman, MD, FHRS, who, during his early work, developed techniques for recording accessory pathway activation potentials in patients with Wolff-Parkinson-White syndrome. He made a small step that was, in fact, a giant leap — the use of the large tip electrode. He presented the first series of cures for atrioventricular reentrant tachycardia by RF catheter ablation. This curative treatment, based mainly on Jackman’s methods, is practiced routinely worldwide.
Dhanunjaya R. Lakkireddy, MBA, MD, FHRS is the Executive Medical Director of the Kansas City Heart Rhythm Institute at HCA Midwest in Overland Park, Kansas. He has specialized clinical expertise and interests in electrophysiology, complex arrhythmia management, heart ablation, left atrial appendage closure, pacemaker and other device implantation and management, cardiac resynchronization therapy & pulmonary artery pressure sensors in heart failure, premature ventricular contractions, syncope, adult congenital and inherited cardiac rhythm disorders and myocarditis.
He is a Professor of Medicine at the University of Missouri, Columbia and a renowned leader in electrophysiology research and education. Dr. Lakkireddy is the recipient of numerous professional honors and awards, including a Professional Leader of the Year from the Asian Chamber of Commerce, Prevention Magazine Integrative Medicine Award and Ingram’s Heroes in Health Care Award.